argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/30/2026

1. META
2. MSFT
3. FTNT
4. CVNA
5. ARM
6. SBUX
7. QCOM
8. MDXG
9. ALGN
10. WAY

Go back to argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

TD Cowen Downgrades Forte Biosciences Inc. (FBRX) to Hold

July 27, 2026 8:14 AM EDT

TD Cowen analyst Yaron Werber downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Buy to Hold with a price target of $77.00.

The analyst comments "We are downgrading FBRX shares to Hold as ARGX has agreed to acquire the company. FBRXs FB102 is a... More